Neutrophil extracellular traps participate in the development of cancer-associated thrombosis in patients with gastric cancer

Table 1 Main clinical and laboratory features of 13 healthy subjects and 63 patients diagnosed with gastric cancer

Characteristics (n = 76, DF = 4)	Control (n = 13)	Stage I (n = 14)	Stage II (n = 15)	Stage III (n = 22)	Stage IV (n = 12)
Male (%)	61.5	50	53.3	72.7	66.6
Age(yr)	58.46 ± 5.43	57.0 ± 10.07	63.07 ± 9.12	60.32 ± 11.54	63.64 ± 9.68
Erythrocytes (× 1012/L)	4.70 ± 0.57	4.46 ± 0.32	4.12 ± 0.83	4.13 ± 0.69	4.03 ± 0.81
Leukocytes (× 109/L)	6.87 ± 2.86	6.57 ± 2.04	8.60 ± 2.54a	8.58 ± 4.66a	10.60 ± 5.25b
Neutrophils (× 109/L)	4.36 ± 3.0	4.62 ± 2.54	6.36 ± 2.82a	6.75 ± 4.92a	8.53 ± 5.46c
Hb (g/L)	140.84 ± 20.31	137.23 ± 10.76	121.29 ± 26.65	121.23 ± 29.72	111 ± 33.23a
PLT (× 109)	259.15 ± 59.0	242.69 ± 52.19	293.29 ± 83.74	250.64 ± 104.63	302.0 ± 156.9
ALB (g/L)	44.84 ± 3.27	43.33 ± 4.84	38.06 ± 6.29	37.39 ± 9.23	35.59 ± 4.08a
PT (s)	11.24 ± 1.03	12.66 ± 4.16	12.42 ± 2.03	12.05 ± 0.86	12.24 ± 1.57
APTT (s)	35.06 ± 2.71	36.03 ± 7.54	34.52 ± 3.46	33.49±3.81	35.08±4.68
D-dimer (mg/L)	53.30 ± 48.16	238.46 ± 265.28c	280.21 ± 269.55c	291.23 ± 262.88c	950.0 ± 743.72d
Fibrinogen (g/L)	2.46 ± 0.43	2.69 ± 0.58	3.67 ± 0.98a	3.19 ± 0.61a	4.68 ± 2.61b

^aP < 0.05 vs healthy control.

^bP < 0.01 vs healthy control.

^cP < 0.001 vs healthy control.

^dP < 0.0001 vs healthy control.

Data are presented as numbers (percentages) or the mean ± SD. DF: Degree of freedom; Hb: Hemoglobin; PLT: Platelets; ALB: Albumin; PT: Prothrombin time; APTT: Activated partial thromboplastin time.